Sai Life Sciences announced its investor presentation for the quarter and half-year ended September 30, 2025. Q2FY26 revenue reached ₹537 Cr, a 36% year-over-year increase, with EBITDA at ₹156 Cr. The company is expanding capabilities in new technologies and modalities, and the presentation highlights financial performance, strategic initiatives, and industry outlook.
Financial Performance Highlights
For Q2FY26, Sai Life Sciences reported a revenue of ₹537 Cr, reflecting a 36% increase compared to Q2FY25. This growth was primarily driven by strong performance in both CRO and CDMO services. EBITDA for the quarter stood at ₹156 Cr, with margins at 29%, benefiting from improved operating leverage and cost management. PAT for Q2FY26 reached ₹84 crore.
The company’s half-year performance (H1FY26) showed a revenue of ₹1,034 Cr, a 53% increase year-over-year. EBITDA for H1FY26 was ₹281 Cr, with a margin of 27.2%. PAT for the same period was ₹144 crore.
Segmental Revenue Growth
The CDMO segment recorded revenues of ₹352 Cr in Q2FY26, up 37% from ₹240 Cr in Q2FY25. The CRO segment reported revenues of ₹185 Cr in Q2FY26, a 19% increase from ₹156 Cr in the previous year’s quarter.
Strategic Initiatives and Expansion
Sai Life Sciences is deepening capabilities in new technologies and modalities, including peptides and oligonucleotides. The company completed the second phase expansion of its Vivarium in Hyderabad, adding 12,000 sq. ft. to enhance preclinical capabilities. They’ve also partnered with Agility Life Sciences (UK) and Centrix Pharma (UK) to offer end-to-end CMC services. Additionally, Sai Life Sciences is committed to sustainability, with near-term GHG reduction targets validated by SBTi.
Future Outlook and Investments
The company continues to invest strategically, with a planned capital expenditure of approximately ₹700 Cr for FY26 to further enhance manufacturing and R&D infrastructure. These investments aim to nearly double the company’s manufacturing capacity by FY27. The new CMC Process R&D Center in Hyderabad is targeted for completion by September 2026, which will double the process R&D capacity.
Industry Analysis
The global CRDMO market is projected to reach USD 303 Bn by 2028, with a 9% CAGR from 2023-2028. The Indian CRDMO industry is among the fastest-growing, projected to grow at 14% CAGR (2023-28).
Source: BSE
